1. Sociedad Española de Ginecología y Obstetricia. Síndrome premenstrual. Documento de consenso de la Sociedad Española de Ginecología y Obstetricia (SEGO). Madrid: SEGO; 2006.. 2. Dysmenorrhea in adolescence. Protocolos SEGO. Prog Obstet Ginecol. 2014; 57 (1), 481-485. 3. ACOG Committee Opinion No. 760: Dysmenorrhea and Endometriosis in the Adolescent. Obstet Gynecol. 2018 Dec;132(6) 4. Garzón-Rodriguez C. Efectividad analgésica del vendaje neuromuscular frente a la Masoterapia local en mujeres con dismenorrea. Cuest. Fisioter. 2013, 42(3): 302-311. 5. Núñez-Claudel, B., Cáceres-Matos, R., Vázquez-Santiago, S., Gil-García, E. Consecuencias de la dismenorrea primaria en adolescentes y mujeres. Revisión Sistemática Exploratoria. iQual. Revista de Género e Igualdad, (3), 132–147. 6. Kho K, Shields J, Diagnosis and Management of Primary Dysmenorrhea. Contemporary OB/GYN Journal, Vol 66 No 5, Volume 66, Issue 05. 7. Marjoribanks J, Ayeleke R, Farquhar C, Proctor M. Nonsteroidal anti-inflammatory drugs for dysmenorrhoea. Cochrane Database of Systematic Reviews 2015, Issue 7. Art. No.: CD001751.. 8. Souto, E.B.; Durazzo, A.; Nazhand, A.; Lucarini, M.; Zaccardelli, M.; Souto, S.B.; Silva, A.M.; Severino, P.; Novellino, E.; Santini, A. Vitex agnus-castus L.: Características principales y perspectivas Nutracéuticas. Bosques 2020, 11, 761.. 9. European Union herbal monograph on Vitex agnus-castus L., fructus EMA/HMPC/606742/2017 Committee on Herbal Medicinal Products (HMPC).. 10. Ebrahimi E, Khayati S, Nemati S, Tavakoli Z, Effects of Magnesium and Vitamin B6 on the Severity of Premenstrual Syndrome Symptoms Journal of Caring Sciences, 2012, 1(4), 183-189. 11. O Chocano-Bedoya P, Manson JE, Hankinson S, Willett W, Johnson S, Chasan-Taber L , Ronnenberg A, Bigelow C, Bertone-Johnson E. Dietary B vitamin intake and incident premenstrual syndrome Am J Clin Nutr 2011;93:1080–6. 12. EFSA (2016), Panel on Dietetic Products, Nutrition and Allergies (NDA); Scientific Opinion on dietary Reference Values for vitamin B6. The EFSA Journal 14(6): 4485. 13. Briskey D, Mallard AR, Rao A Increased Absorption of Palmitoylethanolamide Using a Novel Dispersion Technology System (LipiSperse®). J Nutraceuticals Food Sci Vol.5 No.2:3. 14. Clayton P, Mariko H, Bogoda N, Subah S, Venkatesh R.. “Palmitoylethanolamide: A Natural Compound for Health Management” International Journal of Molecular Sciences 2021, no. 10: 5305.. Borrelli F, Romano B, Petrosino S, Pagano E, Capasso R, Coppola D, Battista G, Orlando P, Di Marzo V, Izzo AA. Palmitoylethanolamide, a naturally occurring lipid, is an orally effective intestinal anti-inflammatory agent. Br J Pharmacol. 2015 Jan;172(1):142-58. 15. Borrelli F, Romano B, Petrosino S, Pagano E, Capasso R, Coppola D, Battista G, Orlando P, Di Marzo V, Izzo AA. Palmitoylethanolamide, a naturally occurring lipid, is an orally effective intestinal anti-inflammatory agent. Br J Pharmacol. 2015 Jan;172(1):142-58. doi: 10.1111/bph.12907. Epub 2014 Dec 1. PMID: 25205418; PMCID: PMC4280974. 16. De Filippis D, Negro L, Vaia M, Cinelli MP, Iuvone T. New insights in mast cell modulation by palmitoylethanolamide. CNS Neurol Disord Drug Targets. 2013 Feb 1;12(1):78-83.. 17. Keppel JM, Kopsky D, Witkamp R. Palmitoylethanolamide (PEA) ‘Promiscuous’ antiinflammatory and analgesic molecule at the interface between nutrition and pharma. PharmaNutrition 2 (2014) 19–25 18. S. Fabris et al. Antioxidant properties of resveratrol and piceid on lipid peroxidation in micelles and monolamellar liposomes. Biophysical Chemistry 135 (2008) 76–83. 19. Mikulski D, Molski M. Quantitative structureantioxidant activity relationship of trans-resveratrol oligomers, trans-4,4’-dihydroxystilbene dimer, trans-resveratrol-3-O-glucuronide, glucosides: trans-piceid, cis-piceid, trans-astringin and trans-resveratrol-4’-O-beta-D-glucopyranoside. Eur J Med Chem. 2010 Jun;45(6):2366-80.. 20. Oliviero F y cols. Antioxidant role of polydatin in an in vitro gout model. Investigación en discapacidad. Vol. 6, Núm. 1Enero-abril 2017 pp 12-16. 21. Giugliano E, Cagnazzo E, Soave I, Lo Monte G, Wenger JM, Marci R. The adjuvant use of N-palmitoylethanolamine and transpolydatin in the treatment of endometriotic pain. Eur J Obstet Gynecol Reprod Biol. 2013 Jun;168(2):209-13.. 22. Stochino E, Pontis A, Cofelice V, Pirarba S, Fais MF, Daniilidis A, Melis I, Paoletti AN, Angioni S. Effect of ultramicronized-palmitoylethanolamide and co-micronized palmitoylethanolamide/polydatin on chronic pelvic pain and quality of life in endometriosis patients: An open-label pilot study. International Journal of Women’s Health 2019:11 443–449. 23. Indraccolo U, Indraccolo SR, Mignini F. Micronized palmitoylethanolamide/ trans-polydatin treatment of endometriosis-related pain: a meta-analysis. Ann Ist Super Sanità 2017 | Vol. 53, No. 2: 125-134. 24. Tartaglia E, Armentano M, Giugliano B, Sena T, Giuliano P, Loffredo C, Mastrantonio P. Effectiveness of the Association N-Palmitoylethanolamine and Transpolidatin in the Treatment of Primary Dysmenorrhea. Journal of Paediatric & Adolescent Gynecology. Vol 28, num 6, p447-450, diciembre 2015. 25. Cobellis L, Castaldi MA, Giordano V, Trabucco E, De Franciscis P, Torella M, Colacurci N. Effectiveness of the association micronized N-Palmitoylethanolamine (PEA)-transpolydatin in the treatment of chronic pelvic pain related to endometriosis after laparoscopic assessment: a pilot study. Eur J Obstet Gynecol Reprod Biol 2011;158(1):82-6.. 26. G Lo Monte, Yo Soave, R Marci. Administration of micronized palmitoylethanolamide (PEA)-transpolidatin in the treatment of chronic pelvic pain in women affected by endometriosis: preliminary results. Minerva Ginecol, 2013 August;65(4):453-63. 27. Di Francesco A, Pizzagallo D. Use of micronized palmitoylethanolamide and trans-polydatin in chronic pelvic pain associated with endometriosis. An open-label study. G Ital Ostet E Ginecol. 2014; XXXVI (2):353–358.